Back to Results
First PageMeta Content
Viruses / GlaxoSmithKline / Onyx Pharmaceuticals / Biologic / Pharmaceutical industry / Oncologists / Medicine / Biotechnology / Oncolytic virus


PSIOXUS THERAPEUTICS STRENGTHENS TEAM WITH TWO APPOINTMENTS Addition of Non-Executive Board Director and Expanded Scientific Advisory Board Position Development Stage Biotech for Growth and Commercialisation LONDON – 1
Add to Reading List

Document Date: 2012-01-18 05:15:55

Open Document

File Size: 353,02 KB

Share Result on Facebook

City

LONDON / /

Company

PsiOxusTherapeutics Ltd. / GlaxoSmithKline / Onyx Pharmaceuticals / PsiOxus Therapeutics Ltd. / Lilly / Bayer Healthcare Pharmaceuticals / /

/

Event

FDA Phase / Employment Change / /

Facility

Bayer Innovation Center / /

IndustryTerm

oncology products / cancer therapies / stage biotechnology company using non-traditional approaches / cancer care / life cycle management / treatment of metastatic cancer / /

MedicalCondition

cancer / novel cancer / metastatic cancer / clinically unmet diseases / /

MedicalTreatment

cancer therapies / /

Organization

Non-Executive Board / Scientific Advisory Board / /

Person

Paolo Paoletti / John Beadle / Terry Hermiston / Oncology / Erik Clausen / Tony Stephenson / /

/

Position

non-executive board director / author / first President / CEO / Vice President of Biologics Research / Director of Oncolytic Virus Research / leader of the newly formed business unit / President / Vice President / Chief Executive Officer / Site Head / the author of nine granted patents within the field / /

Product

MT-102 / ColoAd1 / /

Technology

drug discovery / biotechnology / /

URL

www.PsiOxus.com / /

SocialTag